Xiaomei Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaomei Gong has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Lu Meng
Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
10 shared publicationsShilan Luo
Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
10 shared publicationsPeng Li
Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
6 shared publicationsHongbin Tu
Department of Integrated TCM & Western Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
5 shared publicationsLitang Huang
Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
5 shared publicationsAnqi Zhang
Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
4 shared publications
Latest Publications
- Open Access
- 4 July 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (5)
Radiation induces an EGFR-dependent lactate-epigenetic program underlying synergy with EGFR inhibition
Clinical studies have suggested a therapeutic synergy between EGFR-TKIs and radiotherapy; however, the underlying mechanisms remain incompletely understood, particularly in tumors harboring the acquired resistance mutation EGFR T790M. Using EGFR T790M-positive cell lines, patient-derived organoids (PDOs), and patient-derived xenograft (PDX) models, we systematically investigated radiation responses in EGFR T790M-mutant tumors. Metabolic profiling, protein interaction and phosphorylation analyses, enzyme activity assays, chromatin immunoprecipitation sequencing (ChIP-seq), and DNA damage repair assessments were performed to elucidate the molecular mechanisms of therapeutic synergy between EGFR-TKIs and radiotherapy. We show that EGFR T790M drives a radiation-amplified glycolytic program characterized by enhanced intracellular lactate accumulation. Radiation induces EGFR-dependent tyrosine phosphorylation and activation of lactate dehydrogenase A (LDHA), sustaining lactate production. Rather than being rapidly exported or oxidized, lactate is retained intracellularly and promotes histone H3 lysine lactylation (H3Kla) at promoter regions of DNA repair genes, establishing a repair-permissive chromatin state. This epigenetic priming enhances repair complex assembly, accelerates recruitment of repair factors to DNA double-strand breaks, and facilitates efficient DNA damage resolution. Genetic or pharmacological disruption of the LDHA-lactate axis impairs DNA repair and restores radiosensitivity. In EGFR T790M PDX models, targeting this metabolic pathway significantly enhances radiotherapy efficacy with acceptable toxicity. Our findings identify a previously unrecognized metabolic-epigenetic-repair axis through which EGFR T790M promotes radiotherapy resistance. This study redefines the functional role of EGFR T790M in radiation biology, provides mechanistic insight into the clinical synergy between EGFR inhibition and radiotherapy, and offers a rational framework for developing metabolism-informed combination radiotherapy strategies.
- 4 July 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (5)
Open AccessRadiation induces an EGFR-dependent lactate-epigenetic program underlying synergy with EGFR inhibition
Clinical studies have suggested a therapeutic synergy between EGFR-TKIs and radiotherapy; however, the underlying mechanisms remain incompletely understood, particularly in tumors harboring the acquired resistance mutation EGFR T790M. Using EGFR T790M-positive cell lines, patient-derived organoids (PDOs), and patient-derived xenograft (PDX) models, we systematically investigated radiation responses in EGFR T790M-mutant tumors. Metabolic profiling, protein interaction and phosphorylation analyses, enzyme activity assays, chromatin immunoprecipitation sequencing (ChIP-seq), and DNA damage repair assessments were performed to elucidate the molecular mechanisms of therapeutic synergy between EGFR-TKIs and radiotherapy. We show that EGFR T790M drives a radiation-amplified glycolytic program characterized by enhanced intracellular lactate accumulation. Radiation induces EGFR-dependent tyrosine phosphorylation and activation of lactate dehydrogenase A (LDHA), sustaining lactate production. Rather than being rapidly exported or oxidized, lactate is retained intracellularly and promotes histone H3 lysine lactylation (H3Kla) at promoter regions of DNA repair genes, establishing a repair-permissive chromatin state. This epigenetic priming enhances repair complex assembly, accelerates recruitment of repair factors to DNA double-strand breaks, and facilitates efficient DNA damage resolution. Genetic or pharmacological disruption of the LDHA-lactate axis impairs DNA repair and restores radiosensitivity. In EGFR T790M PDX models, targeting this metabolic pathway significantly enhances radiotherapy efficacy with acceptable toxicity. Our findings identify a previously unrecognized metabolic-epigenetic-repair axis through which EGFR T790M promotes radiotherapy resistance. This study redefines the functional role of EGFR T790M in radiation biology, provides mechanistic insight into the clinical synergy between EGFR inhibition and radiotherapy, and offers a rational framework for developing metabolism-informed combination radiotherapy strategies.
- Open Access
- 8 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6559
Mechanisms Underlying Radioresistance and Reversal Strategies in Non-Small Cell Lung Cancer
Radiotherapy (RT) continues to be a fundamental component in the management of non-small cell lung cancer (NSCLC). Nevertheless, some NSCLC patients do not attain optimal therapeutic outcomes due to the emergence of radioresistance. Improving the effectiveness of RT in NSCLC necessitates a thorough comprehension of the mechanisms that lead to radioresistance. This review delineates various potential mechanisms of radioresistance in NSCLC, encompassing augmented DNA damage repair, cell cycle dysregulation, cancer stem cells (CSCs), epithelial–mesenchymal transition (EMT), tumor hypoxia, an immunosuppressive tumor microenvironment (TME), dysregulation of cell death pathways, metabolic reprogramming, exosome-mediated signaling, genetic mutations, aberrant activation of signaling pathways, and epigenetic modifications. In addition, this study explores various novel strategies aimed at enhancing the radiosensitivity of NSCLC and provides a concise overview of potential biomarkers predictive of RT response, which may contribute to the development of innovative combination therapies to address radioresistance and improve patient outcomes.
- 8 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6559
Open AccessMechanisms Underlying Radioresistance and Reversal Strategies in Non-Small Cell Lung Cancer
Radiotherapy (RT) continues to be a fundamental component in the management of non-small cell lung cancer (NSCLC). Nevertheless, some NSCLC patients do not attain optimal therapeutic outcomes due to the emergence of radioresistance. Improving the effectiveness of RT in NSCLC necessitates a thorough comprehension of the mechanisms that lead to radioresistance. This review delineates various potential mechanisms of radioresistance in NSCLC, encompassing augmented DNA damage repair, cell cycle dysregulation, cancer stem cells (CSCs), epithelial–mesenchymal transition (EMT), tumor hypoxia, an immunosuppressive tumor microenvironment (TME), dysregulation of cell death pathways, metabolic reprogramming, exosome-mediated signaling, genetic mutations, aberrant activation of signaling pathways, and epigenetic modifications. In addition, this study explores various novel strategies aimed at enhancing the radiosensitivity of NSCLC and provides a concise overview of potential biomarkers predictive of RT response, which may contribute to the development of innovative combination therapies to address radioresistance and improve patient outcomes.
- 19 April 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 156, 114671
Urolithin A alleviates radiation pneumonitis by activating PINK1/PRKN-mediated Mitophagy
- 19 April 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 156, 114671
Urolithin A alleviates radiation pneumonitis by activating PINK1/PRKN-mediated Mitophagy
- Open Access
- 1 April 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (4) , 1320-1339
FOXO3a regulation of non-small cell lung cancer radiotherapy resistance through the PINK1/Parkin pathway of protective mitophagy
Background: Radiotherapy resistance has become one of the major causes of radiotherapy failure among patients with non-small cell lung cancer (NSCLC), but its underlying mechanism remains unclear. In recent years, the influence of mitochondrial autophagy on the radiotherapy resistance in treated tumor cells and its regulatory mechanism has become a hotspot in research, which is also the subject of our group research effort. The primary objective of our study is to investigate the mitophagy-associated pathway and the regulatory mechanisms underlying radiotherapy resistance in NSCLC. Methods: We developed biologically stable radiotherapy-resistant NSCLC cell models A549/X and H520/X and verified the radioresistance of these cells. Subsequently, through high-throughput transcriptomic sequencing analysis and experimental verification, we found that the Forkhead box O 3a (FOXO3a) gene and the PINK1/Parkin mitochondrial autophagy pathway in NSCLC radiotherapy-resistant cell lines were consistent and upregulated more reactively than those of parent cells. The effect of gene expression status of the FOXO3a-PINK1/Parkin pathway on the survival outcomes of NSCLC was analyzed in The Cancer Genome Atlas (TCGA) database. Next, we inoculated nude mouse xenografts with small interfering RNA to interfere with the FOXO3a gene and short hairpin RNA to construct radiotherapy-resistant stable strains of NSCLC with stable knockdown of FOXO3a gene. Subsequently, the association and regulation of FOXO3a gene expression levels with radioresistance and mitochondrial autophagy PINK1/Parkin pathway at the cellular and animal levels were determined. Results: The expression level of FOXO3a gene in NSCLC radioresistant cells was significantly positively correlated with the level of mitophagy and the expression level of PINK1/Parkin pathway. Higher expression levels of genes in the FOXO3a-PINK1/Parkin pathway had a negative effect on survival outcomes in NSCLC and were positively correlated with the radioresistance of cells. Conclusions: FOXO3a regulates NSCLC radioresistance by modulating the mitochondrial autophagy PINK1/Parkin pathway, which may serve as a new molecular intervention target and therapeutic entry point for intervening and improving the radioresistance of patients with NSCLC in clinical practice.
- 1 April 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (4) , 1320-1339
Open AccessFOXO3a regulation of non-small cell lung cancer radiotherapy resistance through the PINK1/Parkin pathway of protective mitophagy
Background: Radiotherapy resistance has become one of the major causes of radiotherapy failure among patients with non-small cell lung cancer (NSCLC), but its underlying mechanism remains unclear. In recent years, the influence of mitochondrial autophagy on the radiotherapy resistance in treated tumor cells and its regulatory mechanism has become a hotspot in research, which is also the subject of our group research effort. The primary objective of our study is to investigate the mitophagy-associated pathway and the regulatory mechanisms underlying radiotherapy resistance in NSCLC. Methods: We developed biologically stable radiotherapy-resistant NSCLC cell models A549/X and H520/X and verified the radioresistance of these cells. Subsequently, through high-throughput transcriptomic sequencing analysis and experimental verification, we found that the Forkhead box O 3a (FOXO3a) gene and the PINK1/Parkin mitochondrial autophagy pathway in NSCLC radiotherapy-resistant cell lines were consistent and upregulated more reactively than those of parent cells. The effect of gene expression status of the FOXO3a-PINK1/Parkin pathway on the survival outcomes of NSCLC was analyzed in The Cancer Genome Atlas (TCGA) database. Next, we inoculated nude mouse xenografts with small interfering RNA to interfere with the FOXO3a gene and short hairpin RNA to construct radiotherapy-resistant stable strains of NSCLC with stable knockdown of FOXO3a gene. Subsequently, the association and regulation of FOXO3a gene expression levels with radioresistance and mitochondrial autophagy PINK1/Parkin pathway at the cellular and animal levels were determined. Results: The expression level of FOXO3a gene in NSCLC radioresistant cells was significantly positively correlated with the level of mitophagy and the expression level of PINK1/Parkin pathway. Higher expression levels of genes in the FOXO3a-PINK1/Parkin pathway had a negative effect on survival outcomes in NSCLC and were positively correlated with the radioresistance of cells. Conclusions: FOXO3a regulates NSCLC radioresistance by modulating the mitochondrial autophagy PINK1/Parkin pathway, which may serve as a new molecular intervention target and therapeutic entry point for intervening and improving the radioresistance of patients with NSCLC in clinical practice.
- Open Access
CAML-PSPNet: A Medical Image Segmentation Network Based on Coordinate Attention and a Mixed Loss Function
The problems of missed segmentation with fuzzy boundaries of segmented regions and small regions are common in segmentation tasks, and greatly decrease the accuracy of clinicians’ diagnosis. For this, a new network based on PSPNet, using a coordinate attention mechanism and a mixed loss function for segmentation (CAML-PSPNet), is proposed. Firstly, the coordinate attention module splits the input feature map into horizontal and vertical directions to locate the edge position of the segmentation target. Then, a Mixed Loss function (MLF) is introduced in the model training stage to solve the problem of the low accuracy of small-target tumor segmentation. Finally, the lightweight MobilenetV2 is utilized in backbone feature extraction, which largely reduces the model’s parameter count and enhances computation speed. Three datasets—PrivateLT, Kvasir-SEG and ISIC 2017—are selected for the experimental part, and the experimental results demonstrate significant enhancements in both visual effects and evaluation metrics for the segmentation achieved by CAML-PSPNet. Compared with Deeplabv3, HrNet, U-Net and PSPNet networks, the average intersection rates of CAML-PSPNet are increased by 2.84%, 3.1%, 5.4% and 3.08% on lung cancer data, 7.54%, 3.1%, 5.91% and 8.78% on Kvasir-SEG data, and 1.97%, 0.71%, 3.83% and 0.78% on ISIC 2017 data, respectively. When compared to other methods, CAML-PSPNet has the greatest similarity with the gold standard in boundary segmentation, and effectively enhances the segmentation accuracy for small targets.
Open AccessCAML-PSPNet: A Medical Image Segmentation Network Based on Coordinate Attention and a Mixed Loss Function
The problems of missed segmentation with fuzzy boundaries of segmented regions and small regions are common in segmentation tasks, and greatly decrease the accuracy of clinicians’ diagnosis. For this, a new network based on PSPNet, using a coordinate attention mechanism and a mixed loss function for segmentation (CAML-PSPNet), is proposed. Firstly, the coordinate attention module splits the input feature map into horizontal and vertical directions to locate the edge position of the segmentation target. Then, a Mixed Loss function (MLF) is introduced in the model training stage to solve the problem of the low accuracy of small-target tumor segmentation. Finally, the lightweight MobilenetV2 is utilized in backbone feature extraction, which largely reduces the model’s parameter count and enhances computation speed. Three datasets—PrivateLT, Kvasir-SEG and ISIC 2017—are selected for the experimental part, and the experimental results demonstrate significant enhancements in both visual effects and evaluation metrics for the segmentation achieved by CAML-PSPNet. Compared with Deeplabv3, HrNet, U-Net and PSPNet networks, the average intersection rates of CAML-PSPNet are increased by 2.84%, 3.1%, 5.4% and 3.08% on lung cancer data, 7.54%, 3.1%, 5.91% and 8.78% on Kvasir-SEG data, and 1.97%, 0.71%, 3.83% and 0.78% on ISIC 2017 data, respectively. When compared to other methods, CAML-PSPNet has the greatest similarity with the gold standard in boundary segmentation, and effectively enhances the segmentation accuracy for small targets.
- Open Access
- 23 November 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-19
The impact of Radioresistant-Related Telomere Genes in the prognosis and immune infiltration in lung adenocarcinoma
Lung adenocarcinoma (LUAD), a common subtype of NSCLC, has a high mortality rate. Telomere genes are influenced by radiation therapy, affecting treatment response. Additionally, immune cell presence in the tumor microenvironment plays a crucial role in cancer prognosis. However, the role of Radioresistant-Related Telomere Genes (RRTGs) in LUAD prognosis and immune infiltration remains unclear. In this research, we utilized diverse bioinformatics techniques to examine our personally tested information along with publicly accessible datasets. We conducted a comprehensive study on the genetic and transcriptional differences, predictive significance, and expression profiles of RRTGs. Afterwards, a RRTGs score was developed to forecast the overall survival (OS) and ascertain its reliable predictive capacity for patients with LUAD. Following this, dependable nomograms were developed to enhance the practicality of RRTGs scoring in a clinical setting. Furthermore, the investigation delved into the associations among RRTGs, infiltration of immune cells, prognosis, and clinical treatments of patients. Gene Set Enrichment Analysis (GSEA) was conducted to explore the potential mechanisms by which RRTGs influence the regulation of LUAD. Then, Western blot, qRT-PCR and Immunohistochemistry were used to detect the expression levels of RRTGs in cell lines and LUAD tumor tissues. Our research indicates that certain genes related to telomeres have a notable correlation with the prognosis of patients diagnosed with LUAD. The RRTGs score, which includes three key genes (ARRB1, PLK1, and DSG2), was developed to forecast the OS and its dependable predictive capability for individuals diagnosed with LUAD was ascertained. Afterwards, extremely reliable nomograms were developed to improve the practicality of the RRTGs score. Moreover, as illustrated, genetic characteristics can be utilized to assess the infiltration of immune cells in tumors, as well as clinical attributes and prognosis. RRTGs score characterizes tumor mutational burden, immune activity, and notable survival probabilities in addition. Furthermore, GSEA results revealed that RRTGs may influence LUAD by modulating immune-related pathways in high-risk groups and regulating cell cycle and DNA repair processes in low-risk groups. The RRTGs (ARRB1 and PLK1) were upregulated in A549 cells and radiosensitive NSCLC tissues compared to radioresistant A549 cells and NSCLC tissues. In conclusion, this research emphasizes the significance of RRTGs in the outlook of LUAD. The findings contributed to a better understanding of the link between radiotherapy, telomere-related genes, and prognosis in LUAD, and identified potential therapeutic targets for patients with LUAD.
- 23 November 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-19
Open AccessThe impact of Radioresistant-Related Telomere Genes in the prognosis and immune infiltration in lung adenocarcinoma
Lung adenocarcinoma (LUAD), a common subtype of NSCLC, has a high mortality rate. Telomere genes are influenced by radiation therapy, affecting treatment response. Additionally, immune cell presence in the tumor microenvironment plays a crucial role in cancer prognosis. However, the role of Radioresistant-Related Telomere Genes (RRTGs) in LUAD prognosis and immune infiltration remains unclear. In this research, we utilized diverse bioinformatics techniques to examine our personally tested information along with publicly accessible datasets. We conducted a comprehensive study on the genetic and transcriptional differences, predictive significance, and expression profiles of RRTGs. Afterwards, a RRTGs score was developed to forecast the overall survival (OS) and ascertain its reliable predictive capacity for patients with LUAD. Following this, dependable nomograms were developed to enhance the practicality of RRTGs scoring in a clinical setting. Furthermore, the investigation delved into the associations among RRTGs, infiltration of immune cells, prognosis, and clinical treatments of patients. Gene Set Enrichment Analysis (GSEA) was conducted to explore the potential mechanisms by which RRTGs influence the regulation of LUAD. Then, Western blot, qRT-PCR and Immunohistochemistry were used to detect the expression levels of RRTGs in cell lines and LUAD tumor tissues. Our research indicates that certain genes related to telomeres have a notable correlation with the prognosis of patients diagnosed with LUAD. The RRTGs score, which includes three key genes (ARRB1, PLK1, and DSG2), was developed to forecast the OS and its dependable predictive capability for individuals diagnosed with LUAD was ascertained. Afterwards, extremely reliable nomograms were developed to improve the practicality of the RRTGs score. Moreover, as illustrated, genetic characteristics can be utilized to assess the infiltration of immune cells in tumors, as well as clinical attributes and prognosis. RRTGs score characterizes tumor mutational burden, immune activity, and notable survival probabilities in addition. Furthermore, GSEA results revealed that RRTGs may influence LUAD by modulating immune-related pathways in high-risk groups and regulating cell cycle and DNA repair processes in low-risk groups. The RRTGs (ARRB1 and PLK1) were upregulated in A549 cells and radiosensitive NSCLC tissues compared to radioresistant A549 cells and NSCLC tissues. In conclusion, this research emphasizes the significance of RRTGs in the outlook of LUAD. The findings contributed to a better understanding of the link between radiotherapy, telomere-related genes, and prognosis in LUAD, and identified potential therapeutic targets for patients with LUAD.
- Open Access
- 12 April 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (7) , e7125
PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence
Background: Numerous studies have demonstrated that brain metastases patients may benefit from intracranial radiotherapy combined with immune checkpoint inhibitors (ICIs). However, it is unclear whether this treatment is effective for patients with small cell lung cancer brain metastases (SCLC‐BMs).Methods: We conducted a retrospective study by analyzing medical records of patients with SCLC‐BMs from January 1, 2017 to June 1, 2022. Data related to median overall survival (mOS), median progression‐free survival (mPFS), and intracranial progression‐free survival (iPFS) were analyzed.Results: A total of 109 patients were enrolled, of which 60 received WBRT and 49 received WBRT‐ICI. Compared to the WBRT alone cohort, the WBRT‐ICI cohort showed longer mOS (20.4 months vs. 29.3 months, p = 0.021), mPFS (7.9 months vs. 15.1 months, p < 0.001), and iPFS (8.3 months vs. 16.5 months, p < 0.001). Furthermore, WBRT‐ICI cohort had a better response rate for both BMs. (p = 0.035) and extracranial diseases (p < 0.001) compared to those receiving WBRT alone. Notably, the use of WBRT before ICI was associated with longer mOS compared to the use of WBRT after ICI (23.3 months for the ICI‐WBRT group vs. 34.8 months for the WBRT‐ICI group, p = 0.020).Conclusion: Our results indicated that WBRT combined with immunotherapy improved survival in SCLC‐BMs patients compared to WBRT monotherapy. Administering WBRT prior to ICI treatment is associated with improved survival outcomes compared to WBRT following ICI treatment, for patients with SCLC‐BMs. These findings highlight the significance of conducting further prospective researches on combination strategies of intracranial radiotherapy and ICI in SCLC‐BMs patients.
- 12 April 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (7) , e7125
Open AccessPD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence
Background: Numerous studies have demonstrated that brain metastases patients may benefit from intracranial radiotherapy combined with immune checkpoint inhibitors (ICIs). However, it is unclear whether this treatment is effective for patients with small cell lung cancer brain metastases (SCLC‐BMs).Methods: We conducted a retrospective study by analyzing medical records of patients with SCLC‐BMs from January 1, 2017 to June 1, 2022. Data related to median overall survival (mOS), median progression‐free survival (mPFS), and intracranial progression‐free survival (iPFS) were analyzed.Results: A total of 109 patients were enrolled, of which 60 received WBRT and 49 received WBRT‐ICI. Compared to the WBRT alone cohort, the WBRT‐ICI cohort showed longer mOS (20.4 months vs. 29.3 months, p = 0.021), mPFS (7.9 months vs. 15.1 months, p < 0.001), and iPFS (8.3 months vs. 16.5 months, p < 0.001). Furthermore, WBRT‐ICI cohort had a better response rate for both BMs. (p = 0.035) and extracranial diseases (p < 0.001) compared to those receiving WBRT alone. Notably, the use of WBRT before ICI was associated with longer mOS compared to the use of WBRT after ICI (23.3 months for the ICI‐WBRT group vs. 34.8 months for the WBRT‐ICI group, p = 0.020).Conclusion: Our results indicated that WBRT combined with immunotherapy improved survival in SCLC‐BMs patients compared to WBRT monotherapy. Administering WBRT prior to ICI treatment is associated with improved survival outcomes compared to WBRT following ICI treatment, for patients with SCLC‐BMs. These findings highlight the significance of conducting further prospective researches on combination strategies of intracranial radiotherapy and ICI in SCLC‐BMs patients.
- 26 February 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 130, 111705
G-CSF improving combined whole brain radiotherapy and immunotherapy prognosis of non-small cell lung cancer brain metastases
- 26 February 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 130, 111705
G-CSF improving combined whole brain radiotherapy and immunotherapy prognosis of non-small cell lung cancer brain metastases
- Open Access
Hypoxia-Derived Exosomes Promote Lung Adenocarcinoma by Regulating HS3ST1-GPC4-Mediated Glycolysis
Objective: The diagnosis of lung adenocarcinoma (LUAD) is often delayed due to the typically asymptomatic nature of the early-stage disease, causing advanced-stage LUAD diagnosis in most patients. Hypoxia is widely recognized as a driving force in cancer progression. Exosomes originating from hypoxic tumor cells promote tumorigenesis by influencing glycolysis, migration, invasion, and immune infiltration. Given these insights, our study aimed to explore the role of hypoxia-derived exosomal long non-coding RNA (lncRNA) OIP5-AS1 in LUAD cell lines and mouse models. Materials and Methods: Exosomes were meticulously isolated and authenticated based on their morphology and biomarkers. The interaction between heparan sulfate (glucosamine) 3-O-sulfotransferase 1 (HS3ST1) and Glypican 4 (GPC4) was examined using immunoprecipitation. The influence of the hypoxia-derived exosomal lncRNA OIP5-AS1 on glycolysis was assessed in LUAD cell lines. The effect of the hypoxia-derived exosomal lncRNA OIP5-AS1 on cell proliferation and metastasis was evaluated using colony formation, cell viability, cell cycle, and apoptosis analyses. Its effects on tumor size were confirmed in xenograft animal models. Results: Our study revealed the mechanism of the hypoxia-derived exosomal lncRNA OIP5-AS1 in LUAD progression. We discovered that GPC4 promotes HS3ST1-mediated glycolysis and that the hypoxia-derived exosomal lncRNA OIP5-AS1 enhances glycolysis by regulating miR-200c-3p in LUAD cells. Notably, this lncRNA stimulates LUAD cell proliferation and metastasis and fosters LUAD tumor size via miR-200c-3p. Our findings underscore the potential role of the hypoxia-derived exosomal lncRNA OIP5-AS1 in LUAD progression. Conclusions: The hypoxia-derived exosomal lncRNA OIP5-AS1 promotes LUAD by regulating HS3ST1-GPC4-mediated glycolysis via miR-200c-3p.
Open AccessHypoxia-Derived Exosomes Promote Lung Adenocarcinoma by Regulating HS3ST1-GPC4-Mediated Glycolysis
Objective: The diagnosis of lung adenocarcinoma (LUAD) is often delayed due to the typically asymptomatic nature of the early-stage disease, causing advanced-stage LUAD diagnosis in most patients. Hypoxia is widely recognized as a driving force in cancer progression. Exosomes originating from hypoxic tumor cells promote tumorigenesis by influencing glycolysis, migration, invasion, and immune infiltration. Given these insights, our study aimed to explore the role of hypoxia-derived exosomal long non-coding RNA (lncRNA) OIP5-AS1 in LUAD cell lines and mouse models. Materials and Methods: Exosomes were meticulously isolated and authenticated based on their morphology and biomarkers. The interaction between heparan sulfate (glucosamine) 3-O-sulfotransferase 1 (HS3ST1) and Glypican 4 (GPC4) was examined using immunoprecipitation. The influence of the hypoxia-derived exosomal lncRNA OIP5-AS1 on glycolysis was assessed in LUAD cell lines. The effect of the hypoxia-derived exosomal lncRNA OIP5-AS1 on cell proliferation and metastasis was evaluated using colony formation, cell viability, cell cycle, and apoptosis analyses. Its effects on tumor size were confirmed in xenograft animal models. Results: Our study revealed the mechanism of the hypoxia-derived exosomal lncRNA OIP5-AS1 in LUAD progression. We discovered that GPC4 promotes HS3ST1-mediated glycolysis and that the hypoxia-derived exosomal lncRNA OIP5-AS1 enhances glycolysis by regulating miR-200c-3p in LUAD cells. Notably, this lncRNA stimulates LUAD cell proliferation and metastasis and fosters LUAD tumor size via miR-200c-3p. Our findings underscore the potential role of the hypoxia-derived exosomal lncRNA OIP5-AS1 in LUAD progression. Conclusions: The hypoxia-derived exosomal lncRNA OIP5-AS1 promotes LUAD by regulating HS3ST1-GPC4-mediated glycolysis via miR-200c-3p.